Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
MAPK Signaling Cascades01:07

MAPK Signaling Cascades

Mitogen-activated protein kinase, or MAPK pathway, activates three sequential kinases to regulate cellular responses such as proliferation, differentiation, survival, and apoptosis. The canonical MAPK pathway starts with a mitogen or growth factor binding to an RTK. The activated RTKs stimulate Ras, which recruits Raf or MAP3 Kinase (MAPKKK), the first kinase of the MAPK signaling cascade. Raf further phosphorylates and activates MEK or MAP2 Kinases (MAPKK), which in turn phosphorylates MAP...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

MYOD1 mutation drives cancer stem cell pathways and therapy-resistance in spindle cell/sclerosing rhabdomyosarcoma.

Nature communications·2026
Same author

BRAF V600E-mutated metastatic Wilms tumor with complete response to targeted RAF/MEK inhibition: a post-treatment follow-up case report.

Frontiers in oncology·2026
Same author

Imaging features and the role of image-guided biopsy for assessment of premalignant versus malignant peripheral nerve sheath tumors in neurofibromatosis type 1.

Neuro-oncology practice·2026
Same author

First Report of <i>Haplosporidium edule</i> Infection in the Olive-Green Cockle (<i>Cerastoderma glaucum</i>) from the Northern Adriatic Sea: Expanding Host Range and Geographic Distribution.

Pathogens (Basel, Switzerland)·2026
Same author

Clinical Outcomes Following Surgical Resection for Patients With Malignant Peripheral Nerve Sheath Tumors.

Neurosurgery·2026
Same author

Combined Inhibition of HRAS and MEK Induces Tumor Regression and Restores Myogenic Differentiation in HRAS-Mutant Rhabdomyosarcoma.

Cancer research·2026

Related Experiment Video

Updated: Jul 18, 2026

A Melanoma Patient-Derived Xenograft Model
07:07

A Melanoma Patient-Derived Xenograft Model

Published on: May 20, 2019

BRAF mutation predicts sensitivity to MEK inhibition.

David B Solit1, Levi A Garraway, Christine A Pratilas

  • 1Department of Medicine, Memorial Sloan-Kettering Cancer Center, 1275 York Avenue, New York, New York 10021, USA.

Nature
|November 8, 2005
PubMed
Summary

BRAF-mutant tumors show high sensitivity to MEK inhibitors, unlike RAS-mutant tumors. This finding supports MEK inhibitors as a targeted therapy for BRAF-mutant cancers.

More Related Videos

Characterize Disease-related Mutants of RAF Family Kinases by Using a Set of Practical and Feasible Methods
07:49

Characterize Disease-related Mutants of RAF Family Kinases by Using a Set of Practical and Feasible Methods

Published on: July 17, 2019

Bioluminescence Resonance Energy Transfer (BRET)-Based Assay for Measuring Interactions of CRAF with 14-3-3 Proteins in Live Cells
06:44

Bioluminescence Resonance Energy Transfer (BRET)-Based Assay for Measuring Interactions of CRAF with 14-3-3 Proteins in Live Cells

Published on: March 1, 2024

Related Experiment Videos

Last Updated: Jul 18, 2026

A Melanoma Patient-Derived Xenograft Model
07:07

A Melanoma Patient-Derived Xenograft Model

Published on: May 20, 2019

Characterize Disease-related Mutants of RAF Family Kinases by Using a Set of Practical and Feasible Methods
07:49

Characterize Disease-related Mutants of RAF Family Kinases by Using a Set of Practical and Feasible Methods

Published on: July 17, 2019

Bioluminescence Resonance Energy Transfer (BRET)-Based Assay for Measuring Interactions of CRAF with 14-3-3 Proteins in Live Cells
06:44

Bioluminescence Resonance Energy Transfer (BRET)-Based Assay for Measuring Interactions of CRAF with 14-3-3 Proteins in Live Cells

Published on: March 1, 2024

Area of Science:

  • Oncology
  • Molecular Biology
  • Cancer Genetics

Background:

  • The RAS/RAF/MEK/ERK kinase pathway is frequently activated in human cancers.
  • Gain-of-function mutations in RAS and RAF family members drive this activation.
  • Targeting this pathway is a key strategy in cancer therapy.

Purpose of the Study:

  • To investigate the differential sensitivity of tumors with BRAF versus RAS mutations to MEK inhibition.
  • To elucidate the molecular mechanisms underlying MEK inhibitor sensitivity in BRAF-mutant cells.
  • To evaluate the therapeutic potential of MEK inhibitors in genetically defined tumor subtypes.

Main Methods:

  • Utilized small-molecule MEK inhibitors.
  • Conducted integrated genetic and pharmacologic analyses.
  • Compared MEK inhibition effects in BRAF-mutant, RAS-mutant, and wild-type cells and xenografts.
  • Assessed changes in cyclin D1 protein expression and cell cycle arrest (G1).

Main Results:

  • BRAF-mutant cells exhibited enhanced and selective sensitivity to MEK inhibition compared to wild-type or RAS-mutant cells.
  • This sensitivity was independent of tissue lineage and correlated with cyclin D1 downregulation and G1 arrest.
  • Pharmacological MEK inhibition led to complete tumor growth abrogation in BRAF-mutant xenografts.
  • RAS-mutant tumors showed only partial inhibition with MEK inhibition.

Conclusions:

  • BRAF-mutant tumors display an exquisite dependency on MEK pathway activity.
  • MEK inhibitors represent a rational and effective therapeutic strategy for BRAF-mutant tumors.
  • This study identifies a genetically defined tumor subtype amenable to targeted MEK inhibition.